Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.

JCO precision oncology·2026
Same author

Ditch the drapes: Non-sterile substitution in proctology, a population-based cost and carbon life cycle analysis with early implementation audit.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2026
Same author

Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same authorSame journal

From Guidelines to Practice: Mainstreaming Germline Testing in Prostate Cancer.

JCO oncology practice·2026
Same author

PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

JCO precision oncology·2026

Related Experiment Video

Updated: May 12, 2026

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.1K

Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer.

Sigrid V Carlsson1,2,3,4, Pedro C Barata5, Alan H Bryce6

  • 1Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY.

JCO Oncology Practice
|May 2, 2025
PubMed
Summary

Despite proven benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), many patients remain undertreated due to access barriers. This Prostate Cancer Foundation (PCF) initiative aims to improve care delivery and ensure equitable access to evidence-based treatments.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.3K

Related Experiment Videos

Last Updated: May 12, 2026

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.1K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

12.9K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.3K

Area of Science:

  • Oncology
  • Medical Informatics
  • Health Services Research

Background:

  • Randomized controlled trials confirm combination therapies improve survival and quality of life for metastatic hormone-sensitive prostate cancer (mHSPC).
  • A significant treatment gap persists, with 20%-60% of eligible mHSPC patients undertreated.
  • Disparities in treatment access are influenced by geographic, financial, and systemic factors, as well as patient demographics.

Purpose of the Study:

  • To address critical challenges in mHSPC care delivery and identify strategies to bridge the treatment gap.
  • To analyze real-world evidence and meta-analyses to understand treatment utilization patterns and disparities.
  • To promote equitable access to evidence-based combination therapies for all mHSPC patients.

Main Methods:

  • Convened multi-stakeholder initiative (academia, community practice, industry, patient advocacy).
  • Reviewed real-world evidence from global registries (e.g., IRONMAN) and community databases.
  • Conducted expert discussions and analyzed meta-analyses on mHSPC treatment.

Main Results:

  • Combination therapies (ADT + ARPI or ADT + ARPI + docetaxel) significantly improve outcomes.
  • Inconsistent adoption of combination therapies observed, with undertreatment rates of 20%-60%.
  • Treatment disparities noted across geographic locations, practice types, and patient demographics (e.g., race, urban vs. rural).

Conclusions:

  • Improving mHSPC care requires addressing awareness, standardization, and equitable access to guideline-concordant therapies.
  • Targeted knowledge dissemination, educational resources, and policy advocacy are crucial.
  • Collaborative efforts are essential to enhance survival and quality of life for all mHSPC patients.